Lady Prelox found to improve sexual health and function in peri-menopausal women

Study shows Lady Prelox may improve sexual function and relieve climacteric symptoms in peri-menopausal women

According to a double-blind, placedo-controlled study published in the Journal of Women’s Health Care, Lady Prelox - designated as PACR: Pycnogenol (French pine bark extract) , L-arginine, L-citrulline, Rosvita (rose hip extract) - significantly improved sexual function in women as measured by 60% after 1 month and by 73% after 2 months of treatment compared with baseline readings.

The increase in the placebo group was only 40 and 46%.

In addition, Lady Prelox, which is sold by Pharma Nord in the UK, relieved climacteric symptoms evaluated both by the Kupperman’s index and Women’s Health Questionnaire (WHQ).

The efficacy of Lady Prelox was significantly superior compared with a placebo. No unwanted effects were reported. Sexual function was evaluated by the Female Sexual Function Index (FSFI), which represents the standard tool for the assessment of women’s sexual function.

This clinical study, conducted at the Department of Obstetrics and Gynecology of the Medical University of Sofia, included 80 peri-menopausal women, aged 40 to 50 years, with moderate sexual function problems. They were supplemented with four tablets of Lady Prelox a day for a period of 8 weeks.

Effect of treatment on the women’s sexual function: In placebo-treated women the total FSFI score non-significantly increased from 12.4 to 14.4 after 4 weeks and to 16.6 after 8 weeks. In the Lady Prelox group the FSFI score at baseline was moderately higher than in the placebo group (16.5) and increased to 21.7 and 26.5 after 4 and 8 weeks, respectively. The scores for Lady Prelox after 4 and 8 weeks of treatment were statistically significantly higher than in the placebo group.

A detailed examination of the different domains of the FSFI suggests that Lady Prelox significantly improves desire, arousal, lubrication, orgasm, satisfaction and pain. Comparatively, the domains orgasm and satisfaction were found to improve most prominently.

Effect of treatment on climacteric symptoms: Climacteric symptoms were found to significantly improve with Lady Prelox, after 4 and 8 weeks of treatment. A series of symptoms was found to improve significantly already after 4 weeks as compared with the group of women taking placebo: hot flashes, night sweats, sleep problems, irritability, depressed mood and mental focus. These improvements were maintained until completion of the trial after 8 weeks.

All symptoms except depression were significantly less pronounced than in the placebo group. Symptoms responding particularly well to Lady Prelox were related to cognition (mental focus) and anxiety/fear. Interestingly, the symptom most influenced by the administration of placebo, was the self-perceived attraction.

Safety evaluations suggest that Lady Prelox and the placebo were well tolerated and none of the subjects experienced side-effects. Blood laboratory testing confirmed the safety of the product. A small yet statistical significant lowering of systolic and diastolic blood pressure was noticed with Lady Prelox after 8 weeks. Blood pressure, BMI, lipid profile and TAC significantly improved in the group receiving Lady Prelox.

Conclusion

This study points to a very promising general improvement of well-being for women during the difficult transitional menopausal period. The simultaneous improvement of both sexual as well as climacteric symptoms warrants further investigation also for identification of long-term benefits.

Click here for more information.

Companies